CoChat

Non‐glycaemic effects mediated via GLP‐1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide

Vilsbøll, T., Garber, A. J. · 2012 · Diabetes, Obesity and Metabolism
Cited by 30

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) liraglutide and exenatide can improve glycaemic control by stimulating insulin release through pancreatic β ‐cells in a glucose‐dependent manner. GLP‐1 receptors are not restricted to the pancreas; therefore, GLP‐1 RAs cause additional non‐glycaemic effects. Preclinical and clinical trial data suggest a multitude of additional beneficial effects related to GLP‐1 RA therapy, including improvements in β ‐cell function, systolic blood pressure and body weight. These effects are of a particular advantage to patients with type 2 diabetes, as most are affected by β ‐cell dysfunction, obesity and hypertension. Transient gastrointestinal adverse events, such as nausea and diarrhoea, are also common. To improve gastrointestinal tolerability, an incremental dosing approach is used with liraglutide and exenatide twice daily. A potential protective role for GLP‐1 RAs in the cardiovascular and central nervous systems has been suggested from animal studies and short‐term clinical trials. These effects and other safety aspects of GLP‐1 therapy are currently being investigated in ongoing long‐term clinical studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2012.01579.x

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 30

Metadata

Authors
Vilsbøll, T., & Garber, A. J.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2012-03-08
Volume
14
Issue
s2
Pages
41-49
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1970656852
Cited by
30
References
38
FWCI
4.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non‐glycaemic effects mediated via GLP‐1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. https://app.cochat.ai/papers/10.1111/j.1463-1326.2012.01579.x
The paper
Vilsbøll, T., & Garber, A. J. (2012). Non‐glycaemic effects mediated via GLP‐1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2012.01579.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.